Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Slumped Today

By Prosper Junior Bakiny – Apr 29, 2020 at 4:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead Sciences' remdesivir hits the mark in a clinical trial, which may have dampened optimism for Novavax's potential COVID-19 vaccine.

What happened 

Shares of Novavax (NVAX -6.42%) were down by 10.4% on Wednesday, even though the vaccine maker did not report any news, and the stock market was up today. A possible explanation is that while the biotech company has been racing to develop a vaccine for COVID-19, Gilead Sciences (GILD -1.43%) has announced positive results from a phase 3 clinical trial for remdesivir as a potential treatment for the disease. And so investors are less confident that Novavax will make a fortune off its potential COVID-19 vaccine. 

So what

Gilead's remdesivir has been considered the most promising potential treatment for COVID-19. Back in February, the National Institutes of Health (NIH) started a phase 3 clinical trial investigating the safety and efficacy of remdesivir as a treatment for the coronavirus. Today, both Gilead and the NIH announced positive results from this trial.

Face mask with COVID-19 written on it.

Image source: Getty Images.

According to the NIH, the data from the trial showed that "remdesivir was better than placebo from the perspective of the primary endpoint, time to recovery." The trial indicates that COVID-19 patients who were treated with remdesivir recovered 31% faster than those treated with a placebo.

Now what

Even if remdesivir is approved as a treatment for COVID-19, Novavax's efforts to develop a vaccine may not go to waste, since that would mean there is both a vaccine to prevent the disease and a drug to cure it. So if Novavax's sell-off on the stock market today is indeed linked to the news of Gilead's successful clinical trial, it is a bit of an overreaction. 

With that said, the race to find a vaccine for COVID-19 remains crowded. With at least 70 vaccines for the illness currently in development, there's no good reason to think Novavax will win that race. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$21.00 (-6.42%) $-1.44
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.86 (-1.43%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.